O uso de Sulfato de Magnésio como tratamento adjuvante na fibrilação atrial aguda de alta resposta refratário ao controle de frequência cardíaca: uma revisão de literatura
The use of Magnesium Sulfate as adjunctive treatment in high-response acute atrial fibrillation refractory to heart rate control: a literature review
DOI:
https://doi.org/10.34117/bjdv8n10-202Keywords:
fibrilação atrial, Sulfato de Magnésio, antiarrítmicosAbstract
Introdução: A fibrilação atrial (FA) é uma das arritmias mais comuns com alta morbidade. O controle da frequência cardíaca na fibrilação atrial de alta resposta ventricular estável é um desafio na sala de emergência, sendo que novas drogas, como o sulfato de magnésio, estão sendo avaliadas para o tratamento adjuvante deste tipo de FA. Metodologia: Revisão integrativa utilizando a base de dados da Medline e Scielo. Os descritores utilizados foram: “Atrial fibrilation”, “Magnesium”, “Acute Atrial Fibrilation”, “Intravenous Magnesium”, “Heartbeat control”. Foram analisados apenas artigos em português e inglês publicados até o ano de 2022. Conclusão: O uso de sulfato de magnésio para tratamento adjuvante de FA aguda parece ser controverso, sendo necessário mais estudos para comprovar seu efeito adjuvante no controle da frequência cardíaca da FA aguda. No entanto, diversos centros utilizam de maneira empírica e possuem uma boa resposta terapêutica. Dessa forma, a dose administrada tem um importante papel no efeito clínico desejado, porém não há uma padronização para os casos de fibrilação atrial de alta resposta ventricular refratária ao tratamento de primeira.
References
BOUIDA, W. et al. Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study). Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine, v. 26, n. 2, p. 183–191, fev. 2019.
BRODSKY, M. A. et al. Magnesium therapy in new-onset atrial fibrillation. The American Journal of Cardiology, v. 73, n. 16, p. 1227–1229, 15 jun. 1994.
CARON, M. F. et al. Effects of Intravenous Magnesium Sulfate on the QT Interval in Patients Receiving Ibutilide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, v. 23, n. 3, p. 296–300, 2003.
CHILADAKIS, J. A. et al. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. International Journal of Cardiology, v. 79, n. 2–3, p. 287–291, jul. 2001.
CLEMO, H. F. et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. The American Journal of Cardiology, v. 81, n. 5, p. 594–598, 1 mar. 1998.
CRIPPA, G. et al. Magnesium and cardiovascular drugs: interactions and therapeutic role. Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societa Italiana Di Medicina Interna, v. 14, n. 1, p. 40–45, mar. 1999.
DAVEY, M. J.; TEUBNER, D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Annals of Emergency Medicine, v. 45, n. 4, p. 347–353, abr. 2005.
DELLE KARTH, G. et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Critical Care Medicine, v. 29, n. 6, p. 1149–1153, jun. 2001.
DICARLO, L. A. et al. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. Journal of the American College of Cardiology, v. 7, n. 6, p. 1356–1362, jun. 1986.
FAIRLEY, J. L. et al. Magnesium status and magnesium therapy in cardiac surgery: A systematic review and meta-analysis focusing on arrhythmia prevention. Journal of Critical Care, v. 42, p. 69–77, dez. 2017.
FAVARATO, D. A População Brasileira Apresenta Prevalência de Fibrilação Atrial Semelhante à de Países com Rendas mais Altas, e Baixo Uso de Terapia Anticoagulante. Arquivos Brasileiros de Cardiologia, v. 117, p. 435–436, 20 set. 2021.
FAWCETT, W. J.; HAXBY, E. J.; MALE, D. A. Magnesium: physiology and pharmacology. British Journal of Anaesthesia, v. 83, n. 2, p. 302–320, ago. 1999.
GOULART, A. C. et al. The impact of atrial fibrillation and long-term oral anticoagulant use on all-cause and cardiovascular mortality: A 12-year evaluation of the prospective Brazilian Study of Stroke Mortality and Morbidity. International Journal of Stroke, v. 17, n. 1, p. 48–58, 1 jan. 2022.
GULLESTAD, L. et al. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clinical Cardiology, v. 16, n. 5, p. 429–434, maio 1993.
HAYS, J. V.; GILMAN, J. K.; RUBAL, B. J. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Annals of Emergency Medicine, v. 24, n. 1, p. 61–64, jul. 1994.
HINDRICKS, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal, v. 42, n. 5, p. 373–498, 1 fev. 2021.
HO, K. M.; SHERIDAN, D. J.; PATERSON, T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta‐analysis. Heart, v. 93, n. 11, p. 1433–1440, nov. 2007.
HOFFER, M. et al. Utility of magnesium sulfate in the treatment of rapid atrial fibrillation in the emergency department: a systematic review and meta-analysis. European Journal of Emergency Medicine: Official Journal of the European Society for Emergency Medicine, v. 29, n. 4, p. 253–261, 1 ago. 2022.
HOU, Z. Y. et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. European Heart Journal, v. 16, n. 4, p. 521–528, abr. 1995.
ISERI, L. T. et al. Ionic biology and ionic medicine in cardiac arrhythmias with particular reference to magnesium. American Heart Journal, v. 123, n. 5, p. 1404–1409, maio 1992.
JOSHI, P. P.; DESHMUKH, P. K.; SALKAR, R. G. Efficacy of intravenous magnesium sulphate in supraventricular tachyarrhythmias. The Journal of the Association of Physicians of India, v. 43, n. 8, p. 529–531, ago. 1995.
KIZILTEPE, U. et al. Antiarrhythmic effect of magnesium sulfate after open heart surgery: effect of blood levels. International Journal of Cardiology, v. 89, n. 2–3, p. 153–158, jun. 2003.
MAGALHÃES, L. et al. II Diretrizes Brasileiras de Fibrilação Atrial. Arquivos Brasileiros de Cardiologia, v. 106, n. 4, 2016.
MILLER, S. et al. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart (British Cardiac Society), v. 91, n. 5, p. 618–623, maio 2005.
MORAN, J. L. et al. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study. Critical Care Medicine, v. 23, n. 11, p. 1816–1824, nov. 1995.
RODRIGUEZ, C. J. et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. Annals of Epidemiology, v. 25, n. 2, p. 71- 76.e1, 1 fev. 2015.
SCHNABEL, R. B. et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (London, England), v. 386, n. 9989, p. 154–162, 11 jul. 2015.
SLEESWIJK, M. E. et al. Efficacy of magnesium-amiodarone step-up scheme in critically ill patients with new-onset atrial fibrillation: a prospective observational study. Journal of Intensive Care Medicine, v. 23, n. 1, p. 61–66, fev. 2008.
VAN GELDER, I. C. et al. Rate control in atrial fibrillation. Lancet (London, England), v. 388, n. 10046, p. 818–828, 20 ago. 2016.
WALKER, S.; TAYLOR, J.; HARROD, R. The acute effects of magnesium in atrial fibrillation and flutter with a rapid ventricular rate. Emergency Medicine, v. 8, n. 4, p. 207–213, 1996.
YIIN, G. S. C. et al. Time Trends in Atrial Fibrillation-Associated Stroke and Premorbid Anticoagulation. Stroke, v. 50, n. 1, p. 21–27, jan. 2019.
